Books and Book Chapters

      Kidney-on-a-chip

      Zanetti, F.

      Date published
      Nov 15, 2019
      DOI
      10.1016/B978-0-12-817202-5.00007-3
      ISBN
      978-0-12-817202-5
      Published in
      Organ-on-a-chip: Engineered Microenvironments for Safety and Efficacy Testing
      Editors
      Hoeng, J.; Bovard, D.; Peitsch, M. C.
      Link to publication
      Topic
      Summary

      The kidneys control the body’s balance of fluids and eliminate waste products by regulating the mechanisms of filtration, reabsorption, and secretion. These processes are the main factors in the development of drug-induced kidney diseases. Developing drugs with low nephrotoxic potential would minimize kidney injury; however with the current preclinical research tools available, the toxic potential of candidate compounds is often underestimated. A model that closely resembles the human situation would enable a more accurate prediction of drug-induced nephrotoxicity and reduce the number of animals used in preclinical testing. A kidney-on-a-chip model is the combination of a kidney model (ideally a 3D model) with a platform recreating the microenvironment or structure of the kidney in vivo. This technology promises to overcome the drawbacks of animal models and more accurately resembles the properties of the kidney in vitro and identify drug effects and drug-induced nephrotoxicity.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.